Want to see BRNS full AI Analyst Report?
BRNS Stock Chart & Stats
$0.76
>-$0.01(-0.43%)
At close: 4:00 PM EST
$0.76
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$0.51 - $2.92
Previous CloseN/A
Volume10.26K
Average Volume (3M)124.73K
Market Cap
$25.33M
Enterprise Value-$27.65M
Total Cash (Recent Filing)$67.19M
Total Debt (Recent Filing)$11.01M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding40,848,892
10 Day Avg. Volume97,530
30 Day Avg. Volume124,726
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.38
Price to Sales (P/S)0.00
P/FCF Ratio-0.59
Enterprise Value/Market Cap-1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.69
Enterprise Value/Ebitda0.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthLow leverage and modest debt give a clinical-stage biotherapeutics firm structural flexibility to fund development without heavy interest burdens. This balance sheet profile supports near-term operations and reduces refinancing stress, easing access to debt or structured financings over the next several quarters.
Decisive Shareholder Approval Of SchemeOverwhelming shareholder approval provides procedural certainty for a material corporate transaction, reducing governance risk and enabling strategic restructuring. That clarity can improve the company's ability to execute the planned transaction and attract counterparties or financing tied to the scheme's completion.
Experienced CFO AppointmentHiring a seasoned finance executive strengthens financial stewardship and governance during capital-intensive clinical development. Practical benefits include improved capital planning, credibility with investors and lenders, and tighter cost and reporting controls that can materially reduce execution and funding risk.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flows indicate the business consumes cash each period and lacks internal funding to sustain development. This structural cash burn necessitates repeated external financing, increasing dilution risk and creating dependency on capital markets or partners to maintain operations.
Volatile, Episodic RevenueHighly inconsistent revenue undermines any emerging commercial foundation and complicates forecasting, margin planning, and investment decisions. For a clinical-stage biotherapeutics company, episodic receipts heighten reliance on milestone or one-time payments and hinder sustainable operating leverage.
Nasdaq Compliance And Delisting RiskOngoing listing-compliance pressure and a transfer to the Capital Market signal material share-price and liquidity challenges. Persistent compliance risk can reduce access to public capital, deter institutional interest, and increase financing costs—adversely affecting long-term funding and strategic optionality.
Barinthus Biotherapeutics News
BRNS FAQ
What was Barinthus Biotherapeutics’s price range in the past 12 months?
Barinthus Biotherapeutics lowest stock price was $0.51 and its highest was $2.92 in the past 12 months.
What is Barinthus Biotherapeutics’s market cap?
Barinthus Biotherapeutics’s market cap is $25.33M.
When is Barinthus Biotherapeutics’s upcoming earnings report date?
Barinthus Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 31 days.
How were Barinthus Biotherapeutics’s earnings last quarter?
Barinthus Biotherapeutics released its earnings results on Apr 30, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Barinthus Biotherapeutics overvalued?
According to Wall Street analysts Barinthus Biotherapeutics’s price is currently Overvalued.
Does Barinthus Biotherapeutics pay dividends?
Barinthus Biotherapeutics does not currently pay dividends.
What is Barinthus Biotherapeutics’s EPS estimate?
Barinthus Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does Barinthus Biotherapeutics have?
Barinthus Biotherapeutics has 40,848,892 shares outstanding.
What happened to Barinthus Biotherapeutics’s price movement after its last earnings report?
Barinthus Biotherapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went up 8.514%.
Which hedge fund is a major shareholder of Barinthus Biotherapeutics?
Currently, no hedge funds are holding shares in BRNS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Barinthus Biotherapeutics
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Technical Analysis
Collplant Holdings
―
ALX Oncology Holdings
―
Aligos Therapeutics
―
CytoMed Therapeutics Limited
―
Boundless Bio Inc.
―
Ownership Overview
―
Insiders
0.03% Mutual Funds
21.69% Other Institutional Investors
78.29% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---